• ZMapp, developed by Mapp Biopharmaceutical, was used in August to treat several patients in the ongoing Ebola virus outbreak
  • Five of the seven patients who received ZMapp survived
  • Now knowing how ZMapp targets Ebola, scientists can compare all newly discovered anti-Ebola antibodies and formulate a better immunotherapeutic drug

Share This Article